6,320 Shares in IQVIA Holdings Inc. $IQV Acquired by North Star Asset Management Inc.

North Star Asset Management Inc. acquired a new stake in IQVIA Holdings Inc. (NYSE:IQV) in the 2nd quarter, according to its most recent disclosure with the SEC. The fund acquired 6,320 shares of the medical research company’s stock, valued at approximately $1,221,000.

Several other large investors also recently modified their holdings of the stock. Brighton Jones LLC grew its stake in IQVIA by 244.4% during the fourth quarter. Brighton Jones LLC now owns 3,575 shares of the medical research company’s stock worth $703,000 after buying an additional 2,537 shares in the last quarter. Empowered Funds LLC raised its position in shares of IQVIA by 102.1% in the 1st quarter. Empowered Funds LLC now owns 9,728 shares of the medical research company’s stock valued at $1,715,000 after buying an additional 4,915 shares in the last quarter. Sivia Capital Partners LLC bought a new stake in shares of IQVIA during the 2nd quarter worth approximately $514,000. First Trust Advisors LP boosted its position in shares of IQVIA by 14.8% during the 2nd quarter. First Trust Advisors LP now owns 92,015 shares of the medical research company’s stock worth $14,501,000 after acquiring an additional 11,845 shares in the last quarter. Finally, NewEdge Advisors LLC increased its stake in IQVIA by 5.4% in the second quarter. NewEdge Advisors LLC now owns 22,731 shares of the medical research company’s stock valued at $3,582,000 after acquiring an additional 1,155 shares during the last quarter. 89.62% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, insider Keriann Cherofsky sold 558 shares of the company’s stock in a transaction that occurred on Wednesday, July 29th. The stock was sold at an average price of $245.21, for a total value of $136,827.18. Following the sale, the insider directly owned 2,989 shares in the company, valued at $732,932.69. This represents a 15.73% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Eric Sherbet sold 5,000 shares of the stock in a transaction that occurred on Wednesday, July 29th. The shares were sold at an average price of $249.16, for a total transaction of $1,245,800.00. Following the sale, the insider directly owned 20,999 shares of the company’s stock, valued at $5,232,110.84. This represents a 19.23% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 12,913 shares of company stock worth $3,098,793. Corporate insiders own 1.70% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have weighed in on the company. JPMorgan Chase & Co. upped their target price on IQVIA from $225.00 to $285.00 and gave the stock an “overweight” rating in a research note on Wednesday, July 29th. William Blair raised IQVIA to a “strong-buy” rating in a report on Tuesday, July 28th. Barclays restated an “overweight” rating on shares of IQVIA in a research report on Tuesday, July 28th. HSBC reiterated a “buy” rating and issued a $240.00 target price on shares of IQVIA in a research report on Monday, July 6th. Finally, TD Cowen boosted their target price on IQVIA from $233.00 to $288.00 and gave the stock a “buy” rating in a research note on Wednesday, July 29th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $241.88.

IQVIA Trading Down 0.7%

Shares of NYSE IQV opened at $260.48 on Friday. The firm has a 50 day moving average price of $222.14 and a two-hundred day moving average price of $189.62. The stock has a market cap of $42.88 billion, a P/E ratio of 32.32, a price-to-earnings-growth ratio of 2.24 and a beta of 1.18. IQVIA Holdings Inc. has a 52-week low of $154.50 and a 52-week high of $265.25. The company has a debt-to-equity ratio of 2.18, a quick ratio of 0.71 and a current ratio of 0.71.

IQVIA (NYSE:IQV) last issued its quarterly earnings data on Tuesday, July 28th. The medical research company reported $3.15 earnings per share for the quarter, topping the consensus estimate of $3.03 by $0.12. The company had revenue of $4.37 billion for the quarter, compared to analysts’ expectations of $4.30 billion. IQVIA had a net margin of 8.10% and a return on equity of 30.25%. IQVIA’s revenue for the quarter was up 8.7% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.81 earnings per share. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. As a group, equities analysts forecast that IQVIA Holdings Inc. will post 11.57 EPS for the current year.

IQVIA announced that its board has authorized a stock buyback program on Thursday, May 7th that permits the company to buyback $2.00 billion in shares. This buyback authorization permits the medical research company to repurchase up to 6.8% of its stock through open market purchases. Stock buyback programs are usually an indication that the company’s leadership believes its stock is undervalued.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.